Federico Greco^1,2,*, Marco Cataldo³, Valerio D’Andrea^2,4, Luca Pugliese⁵, Andrea Panunzio⁶, Alessandro Tafuri⁶, Bruno Beomonte Zobel^2,4, Carlo Augusto Mallio^2,4

Canadian Journal of Urology, Vol.32, No.5, pp. 433-443, 2025, DOI:10.32604/cju.2025.068390 - 30 October 2025

Abstract Background: Radiogenomics offers a non-invasive approach to correlate imaging features with tumor molecular profiles. This study aims to identify computed tomography (CT) imaging characteristics associated with positive NIPA-like domain containing 4 (NIPAL4) expression in clear cell renal cell carcinoma (ccRCC) and to develop a radiogenomic predictive model to support personalized risk stratification. Methods: A retrospective analysis was conducted on 241 ccRCC patients from The Cancer Genome Atlas (TCGA) and The Cancer Imaging Archive (TCIA) databases. Clinical, pathological, and CT features were compared between NIPAL4-positive and NIPAL4-negative groups. A penalized logistic regression model was built to… More >

Jiayin Peng^1,2,#, Yijun Xue^2,#, Zhiren Cai², Zhaoguan Li², Kangyan Han², Xiaoqi Lin², Yutong Li^1,*, Yumin Zhuo^1,*

Oncology Research, Vol.33, No.10, pp. 3127-3154, 2025, DOI:10.32604/or.2025.067340 - 26 September 2025

Abstract Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy associated with limited treatment options and poor prognosis. Emerging studies suggest that the actin-regulating protein actin-related protein 2/3 complex subunit 1B (ARPC1B), a key regulatory protein within the actin cytoskeleton, could play a pivotal role in ccRCC progression. The current study aimed to uncover the biological functions of ARPC1B and the molecular mechanisms driving its effects in ccRCC. Methods: ARPC1B expression and prognostic implications were analyzed using data sourced from the Gene Expression Profiling Interactive Analysis (GEPIA) platform, immunohistochemical (IHC) staining on 150 tumor… More >

NAIXIONG PENG, YUEFENG CAI, DONG CHEN, LING DENG, ZEJIAN ZHANG, WEI LI^*

Oncology Research, Vol.33, No.2, pp. 347-356, 2025, DOI:10.32604/or.2024.056039 - 16 January 2025

Abstract Background: Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood. Methods: The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC. The expression of EGR1 in 55 ccRCC tissues was evaluated using immunohistochemistry. The link between EGR1 expression and clinicopathological variables was examined through an analysis. Gain-of-function assays were employed to… More >

WEIGANG REN^1,#, JING LI^2,#, RUIJIANG ZENG^3,4, LIANG ZHU^3,4,*

BIOCELL, Vol.48, No.9, pp. 1323-1330, 2024, DOI:10.32604/biocell.2024.051747 - 04 September 2024

Abstract Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys. ccRCC is well known as a type of tumour with immunogenicity. Immune checkpoint inhibitors (ICIs) aim to enhance the anticancer immune response in ccRCC by blocking programmed cell death 1 ligand 1/programmed death 1 (PD-L1/PD-1) pathways. In a previous study, we showed that RING finger protein 26 (RNF26) degrades chromobox 7 (CBX7) to activate the tumor necrosis factor (TNF) in ccRCC. Methods: We analyzed The Cancer Genome Atlas (TCGA)… More > Graphic Abstract

KAIWEN TIAN^#, HANZHONG CHEN^#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG^*, JIUMIN LIU^*

BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737 - 06 May 2024

Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

RENLONG ZHOU^1,2,#, SHUANG LI^3,#, XILIN XIAO^1,*

BIOCELL, Vol.47, No.11, pp. 2397-2408, 2023, DOI:10.32604/biocell.2023.030281 - 27 November 2023

Abstract Background: In many cancer types, aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) has been found to be associated with tumor cell proliferation and prognosis. However, the role of ARNT2 in clear cell renal cell carcinoma (ccRCC) has not been completely elucidated. In this study, the potential role of ARNT2 in ccRCC development was characterized. Methods: A pan-cancer dataset (TCGA-TARGET-GTEx) was accessed from UCSC Xena Data Browser. ARNT2 expression in normal and tumor samples was compared. Univariate Cox regression was performed to evaluate the prognostic value of ARNT2. Single sample gene set enrichment analysis (ssGSEA) was… More >

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*

Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942 - 22 May 2023

Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More > Graphic Abstract

WEI BAO^1,#, QIANGUANG HAN^2,#, XIAO GUAN³, ZIJIE WANG², MIN GU^1,2,*

Oncology Research, Vol.31, No.2, pp. 181-192, 2023, DOI:10.32604/or.2023.028051 - 10 April 2023

Abstract Background: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. Methods: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk… More >

Dayu Tian¹, Yang Shi¹, Li Lei¹, Xiangmin Qiu¹, Tao Song^2,*, Qianyin Li^1,*

Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838 - 29 June 2022

Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related… More >

MAGDALENA RUDZIŃSKA-RADECKA^*

BIOCELL, Vol.46, No.8, pp. 1893-1901, 2022, DOI:10.32604/biocell.2022.019724 - 22 April 2022

Abstract Clear cell renal cell carcinoma (KIRC) is the most common and aggressive malignancy subtype of renal neoplasm that arises from proximal convoluted tubules. It is characterized by poor clinical outcomes and high mortality of patients due to the lack of specific biomarkers for varying stages of the disease and no effective treatment. Proteases are associated with the development of several malignant tumors in humans by their ability to degrade extracellular matrices, facilitating metastasis. Herein, differentially expressed genes in KIRC cases compared to healthy kidneys were screened out from the Gene Expression Profiling Interactive Analysis (GEPIA)… More >